Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBPO China Biologic Products	$119.99 +1.7%	$119.23	$99.74 ▼ $120.05	$4.72B	0.47	148,695 shs	24,016 shs
HALO Halozyme Therapeutics	$59.79 -3.4%	$59.74	$37.73 ▼ $66.00	$7.37B	1.32	1.39 million shs	1.05 million shs
IOVA Iovance Biotherapeutics	$3.06 -6.0%	$4.68	$2.96 ▼ $14.23	$987.24M	1.05	7.20 million shs	8.68 million shs
MNTA Momenta Pharmaceuticals	$52.48	$52.44	$12.21 ▼ $52.53	$6.25B	1.71	1.94 million shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBPO China Biologic Products	0.00%	0.00%	0.00%	0.00%	0.00%
HALO Halozyme Therapeutics	-1.75%	-3.97%	+6.50%	+29.70%	+53.91%
IOVA Iovance Biotherapeutics	-8.19%	-10.47%	-17.09%	-57.52%	-76.80%
MNTA Momenta Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	4.1537 of 5 stars	1.3	1.0	0.0	4.4	3.5	2.5	4.4
IOVA Iovance Biotherapeutics	4.1074 of 5 stars	4.4	1.0	0.0	4.2	1.5	2.5	0.6
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBPO China Biologic Products	0.00	N/A	N/A	N/A
HALO Halozyme Therapeutics	2.60	Moderate Buy	$62.78	5.00% Upside
IOVA Iovance Biotherapeutics	2.88	Moderate Buy	$20.25	562.85% Upside
MNTA Momenta Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HALO, MNTA, CBPO, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/6/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/3/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $15.00
3/3/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/3/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $30.00
2/28/2025	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
2/28/2025	IOVA Iovance Biotherapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$7.50 ➝ $6.00
2/28/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
2/20/2025	HALO Halozyme Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
2/19/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $72.00
2/4/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
1/31/2025	IOVA Iovance Biotherapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $7.50

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBPO China Biologic Products	$503.70M	9.38	$5.01 per share	23.93	$45.09 per share	2.66
HALO Halozyme Therapeutics	$1.02B	7.27	$4.84 per share	12.35	$2.95 per share	20.27
IOVA Iovance Biotherapeutics	$164.07M	6.11	N/A	N/A	$2.28 per share	1.34
MNTA Momenta Pharmaceuticals	$23.87M	261.69	N/A	N/A	$4.59 per share	11.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBPO China Biologic Products	$138.81M	$4.28	33.52	27.90	N/A	27.43%	8.32%	7.64%	N/A
HALO Halozyme Therapeutics	$281.59M	$3.43	17.39	9.61	0.42	43.74%	157.78%	25.34%	5/6/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$444.04M	-$1.30	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	5/8/2025 (Estimated)
MNTA Momenta Pharmaceuticals	-$290.05M	-$3.03	N/A	N/A	N/A	-757.61%	-61.44%	-45.28%	N/A

Latest HALO, MNTA, CBPO, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/27/2025	Q4 2024	IOVA Iovance Biotherapeutics	-$0.26	-$0.26	N/A	-$0.26	$72.17 million	$73.69 million
2/18/2025	Q4 2024	HALO Halozyme Therapeutics	$1.17	$1.19	+$0.02	$1.06	$285.74 million	$298.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBPO China Biologic Products	N/A	12.01	10.13
HALO Halozyme Therapeutics	4.14	7.80	9.15
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
MNTA Momenta Pharmaceuticals	N/A	6.38	6.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBPO China Biologic Products	34.77%
HALO Halozyme Therapeutics	97.79%
IOVA Iovance Biotherapeutics	77.03%
MNTA Momenta Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CBPO China Biologic Products	2.73%
HALO Halozyme Therapeutics	2.90%
IOVA Iovance Biotherapeutics	12.10%
MNTA Momenta Pharmaceuticals	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBPO China Biologic Products	2,269	39.36 million	N/A	Optionable
HALO Halozyme Therapeutics	390	123.53 million	120.20 million	Optionable
IOVA Iovance Biotherapeutics	500	327.88 million	267.90 million	Optionable
MNTA Momenta Pharmaceuticals	131	119.03 million	N/A	Optionable

HALO, MNTA, CBPO, and IOVA Headlines

Recent News About These Companies

Stephanie Schonewald

October 31, 2024 | ipwatchdog.com

J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker

October 17, 2024 | fiercebiotech.com

J&J launches gMG market bid with nipocalimab filing

September 2, 2024 | pharmaphorum.com

Johnson & Johnson Files for First FDA OK of Nipocalimab

August 31, 2024 | marketwatch.com

Impact of Bleeding Complications on Outcomes After Percutaneous Coronary Interventions

April 12, 2024 | medscape.com

Acquired patents aid J&J defense of top-selling drug from biosimilar challenge

March 30, 2023 | biopharmadive.com

Genoptix, Momenta Shares Headed for Gains

February 28, 2023 | thestreet.com

Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports

August 13, 2022 | xconomy.com

Patent infringement cases move to the fast lane in India

June 13, 2022 | thepharmaletter.com

Johnson & Johnson, Momenta Pharma file lawsuit against Natco, Mylan in US

May 25, 2022 | msn.com

Eastman Kodak, Rambus: After-Hours Trading

May 1, 2022 | thestreet.com

Innovation leader

April 8, 2022 | udel.edu

Momenta Pharmaceuticals, Inc. Common Stock (MNTA)

August 3, 2021 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO, MNTA, CBPO, and IOVA Company Descriptions

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Halozyme Therapeutics NASDAQ:HALO

$59.79 -2.13 (-3.45%)

As of 01:41 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$3.06 -0.20 (-6.00%)

As of 01:41 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Momenta Pharmaceuticals NASDAQ:MNTA

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time